Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2013. The document serves as a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The primary purpose of this filing is to announce a corporate governance change regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate announcement rather than a financial results report.
Material Changes
The material change reported is the appointment of Mr. Hans Wijers to the GSK Board as a Non-Executive Director, effective April 1, 2013. This appointment is subject to shareholder approval at the 2013 Annual General Meeting. Mr. Wijers brings significant experience as the former CEO and Chairman of AkzoNobel and currently serves as Chairman designate of Heineken N.V. and Deputy Chairman of Royal Dutch Shell.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995. It notes that actual results may differ materially from projections due to risks and uncertainties. Specific risk factors are referenced as being described in the 'Financial review & risk' section of the company's Annual Report 2011 (Exhibit 15.2 to the 2011 Form 20-F). No specific financial guidance or outlook for 2013 is provided in this text.
Important Facts for Investors to Verify
- Confirmation of shareholder approval for Mr. Wijers' appointment at the May 2013 Annual General Meeting.
- Mr. Wijers' compensation structure: an annual fee of £85,000, with at least 25% paid in Ordinary Shares.
- The updated composition of the Board of Directors following the appointment.
- Review of the 2011 Annual Report for detailed risk factors affecting operations.